Zymeworks To Host Second Quarter 2023 Results Conference Call

2 years ago

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

QM Racing Inc., a 100% owned subsidiary of Quad M Solutions, Inc., signs definitive agreement to purchase 100 percent of REV Technologies.

2 years ago

Garland, TX, July 19, 2023 (GLOBE NEWSWIRE) -- QM Racing, Inc. (QM Racing), a subsidiary of Quad M Solutions, Inc., (OTC:…

Carmot Therapeutics Appoints Charles W. Newton to Board of Directors

2 years ago

Biotechnology industry executive and former healthcare investment banker with proven track record of advising management teams on corporate and financial…

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

2 years ago

Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023SCOTTSDALE,…

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

2 years ago

– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023…

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

2 years ago

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are…

First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering

2 years ago

BOCA RATON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”),…

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

2 years ago

NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

2 years ago

First-in-human intradermal administration of CoronaTcP™ was generally well-toleratedEvidence for generation of virus-specific effector and memory CD8+ T cellsData reinforce findings…

Oculis to Present at OIS Retina Innovation Summit

2 years ago

ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company…